As HDACis have been previously reported to reduce mutp53 in several cancer cell types [13,14] and the reduction of mutant p53 represents a therapeutic strategy against gliomas [6], we next evaluated the mutp53 expression level in U373 cells undergoing PBA treatment. Here, TP53 is linked to cancer.